January 13, 2025 - 02:56

ALAMEDA, Calif., January 12, 2025—Exelixis, Inc. has announced its preliminary unaudited financial results for the fiscal year 2024, alongside financial guidance for the upcoming fiscal year 2025. The company is optimistic about the potential for significant advancements in clinical and regulatory efforts, particularly concerning its cabozantinib franchise.
In 2025, Exelixis plans to focus on executing its clinical programs and anticipates multiple data readouts for zanzalintinib, as well as developments across its diverse pipeline of small molecules and biotherapeutics. The company aims to leverage its existing assets while exploring new opportunities to enhance its market position.
With a clear strategy in place, Exelixis is poised for a year of growth, innovation, and impactful milestones that could shape the future of its therapeutic offerings. The commitment to advancing patient care remains at the forefront of Exelixis's mission as it navigates the challenges and opportunities ahead.
February 24, 2026 - 08:03
Japan Maintaining Close Dialogue With U.S. on Forex, Finance Minister SaysFinance Minister Shunichi Suzuki confirmed that Japanese authorities remain in close and constant dialogue with their United States counterparts regarding recent foreign exchange movements. The...
February 23, 2026 - 19:53
Stock market today: Dow drops 800 points as S&P 500, Nasdaq slide on Trump tariff fears, AI 'scare trade'Wall Street opened the week with a sharp sell-off, as investors grappled with renewed fears of a global trade war and a significant pullback in the high-flying technology sector. The Dow Jones...
February 23, 2026 - 02:41
Mastercard Partnerships With Ericsson And Cloudflare Reshape Digital Finance RoleFinancial services giant Mastercard has unveiled two significant partnerships aimed at expanding its influence in digital finance and cybersecurity. The collaborations with telecommunications...
February 22, 2026 - 22:14
Opinion - Efforts to fight online financial scams are missing the markCurrent efforts to protect consumers from online financial fraud are increasingly seen as misdirected. While large technology and social media companies are often the primary targets of regulatory...